Document is current
Any future updates will be listed below
-
Authors
,
Kasela, Silva https://orcid.org/0000-0003-4362-0034
,
Ortega, Victor E.
Martorella, Molly
Garudadri, Suresh
Nguyen, Jenna
Ampleford, Elizabeth
Pasanen, Anu
Nerella, Srilaxmi
Buschur, Kristina L.
Barjaktarevic, Igor Z.
Barr, R. Graham
Bleecker, Eugene R.
Bowler, Russell P.
Comellas, Alejandro P.
Cooper, Christopher B.
Couper, David J.
Criner, Gerard J.
Curtis, Jeffrey L.
Han, MeiLan K.
Hansel, Nadia N.
Hoffman, Eric A.
Kaner, Robert J.
Krishnan, Jerry A.
Martinez, Fernando J.
McDonald, Merry-Lynn N.
Meyers, Deborah A.
Paine, Robert 3rd
Peters, Stephen P.
Castro, Mario
Denlinger, Loren C.
Erzurum, Serpil C.
Fahy, John V.
Israel, Elliot
Jarjour, Nizar N.
Levy, Bruce D.
Li, Xingnan
Moore, Wendy C.
Wenzel, Sally E.
Zein, Joe
Langelier, Charles
Woodruff, Prescott G.
Lappalainen, Tuuli
Christenson, Stephanie A.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (R01MH106842)
National Heart, Lung, and Blood Institute (R01HL142028, R01HL142028, R01HL142992, R01HL137880, K23HL123778, R01HL121774, U01HL137880, R01HL142028, T32HL144442, T32HL144442)
National Institute of General Medical Sciences (R01GM122924, R01GM124486)
National Human Genome Research Institute (UM1HG008901, F30HG011194)
- License Information
-
More Information
Article History
Received: 10 November 2020
Accepted: 11 March 2021
First Online: 21 April 2021
Declarations
:
: The SPIROMICS study was approved by the Institutional Review Boards at each cooperating institutions: Columbia University IRB 2 (AAAE9315), University of Iowa IRB-01 (201308719), Johns Hopkins IRB-5 (NA_00035701), UCLA Medical IRB 1 (MIRB1) (10001740/18-000403), University of Michigan IRBMED B1 Board (HUM00036346/ HUM00141222), National Jewish Health IRB (HS2678), UCSF IRB Parnassus Panel (10-03169), Temple University IRB A2 (21416), U of Alabama at Birmingham IRB #2 (120906004), University of Illinois IRB #3 (2013-0939), University of Utah IRB Panel Review Board 5 (00027298/ 00108836), Wake Forest University IRB #5 (00012805/00048727), UNC Non-Biomedical IRB (10-0048), UCLA Medical IRB 1 (MIRB1) (18-000458), and University of Iowa IRB-01 (201003733). All participants provided written informed consent. The SARP and MAST studies were approved by the appropriate institutional review board at the participating sites and all participants provided written informed consent. The research conformed to the principles of the Helsinki Declaration.
: Not applicable
: S.A.C. advises for AstraZeneca, GlaxoSmithKline, Glenmark Pharmaceuticals, and Amgen, gave invited lectures to Sonovion and Genentech, and writes for UpToDate. T.L. advises and has equity in Variant Bio and is a member of the scientific advisory board of Goldfinch Bio. V.E.O. has served and currently serves on Independent Data and Monitoring Committee for Regeneron and Sanofi for COVID-19 therapeutic clinical trials unrelated to the current manuscript. The remaining authors declare that they have no competing interests.
